Allied Academies invites all the participants from all over the world to attend “International Conference on Biomarkers & Clinical Research” held at Atlanta, Georgia, USA on November 27-28, 2017 which includes prompt Keynote Presentations, Special Sessions, Workshops, Symposiums, Oral talks, Poster Presentations and Exhibitions.
Theme: Explore the latest Biomarkers Development in Health and Clinical Research
are important for streamlining drug discovery and development. In addition,
biomarkers can be widely used as a tool for disease diagnosis, personalized
medication in clinical research. Study design and statistical analysis for
biomarker research incorporates various tools from bioinformatics. It further
involves patient segmentation and stratification by successful integration of
diagnostic tools and clinical data annotation inclusive of classification
distribution metrics and pattern recognition. The global market for biomarkers
in data statistics is estimated at about $2.4 billion in 2011 and further
projected to reach $7.6 billion by 2017 registering a CAGR of 18.3% during the
period 2007-2017. The organizations involved are Affymetrix, Agilent
Technologies, Biomax Informatics, Illumina, Qiagen etc among others across the
Biomarkers Congress 2017 will provide an excellent opportunity for the budding scientists and young researchers through its special initiatives like Young Researcher Forum, Poster Presentation and E-poster and Live Streaming, B2B and Scientific Meetings.
Why Biomarkers Congress 2017?
Biomarkers Congress 2017 will provide a stimulating scientific environment and a platform for the participants to exchange ideas, establish research collaboration and networking by attending the Biomarkers conferences. It will be amazing opportunity for the attendees to explore the beautiful city of Atlanta with gaining knowledge, sure to raise insights, conflate present with future and cogitate on ideas and reality in Biomarkers meetings.
Allied Academies is glad to announce the 2017 conference in the Oncology and Cancer series, the ‘International Conference on Biomarkers & Clinical Research’ which is to be held on November 27-28, 2017 at Atlanta, Georgia, USA.
Biomarkers Congress 2017 will enable to put forth the holistic scientific approach to validate the existing and development of novel biomarkers as to better understanding of diseases and diagnosis.
Allied Academies has been instrumental in Conducting International Meetings for 20 years and very excited to expand in Medical and Health Care Fields. Allied Academics promotes peer reviewed healthcare information through meetings, scholarly journals, and training to leading academic, business and research institutes across the healthcare and life science industries.
Sessions and Tracks
Track 1: Biomarkers
Biomarker or a
biological marker is a quantitative substance present in an organism that acts
as an indicator of biological conditions like pharmacological (therapeutic),
pathogenic (toxic) or any normal biological processes. It helps in the
prediction of the diseases and the biochemical reactions that occur inside the
organism. These Biomarkers are introduced into an organism in traces to
validate the function of the organs and other health aspects. Biomarkers can be
a gene, genetic product, enzyme, hormone or a molecule which have various
activities and functions inside the organism. There are two kinds of biomarkers
– biomarkers of exposure, involving risk prediction and biomarkers of disease,
used in screening, diagnosis and monitoring the disease progression. There are
various types of biomarkers which include fluorescent biomarkers, blood-based
biomarkers, pro-inflammatory biomarkers, hematological biomarkers and obesity
Track 2: Molecular Biomarkers
Biomarkers that are in molecular form are called Molecular Biomarkers. These molecular biomarkers involve in the processes of disease diagnosis, disease prognosis, prediction and calculation of the treatment response and the evaluation of the biomarkers. The molecular biomarkers are developed and validated to use it in drug development processes. There are various molecular biomarkers like protein biomarkers, nucleic acid biomarkers, small molecule biomarkers, lipid biomarkers and micro RNA biomarkers.
Track 3: Cancer Biomarkers
Biomarkers have a greater role in the study of cancer, which involves in the risk assessment, screening, diagnosis, prognosis, prediction of the treatment response, and monitoring of the progression of the disease. As the biomarkers play an important role in every condition of the disease, the biomarkers is evaluated accurately, including analytical validation, clinical validation and clinical utility assessment, incorporating into routine clinical care. Cancer Biomarkers are also useful in the process of developing drug targets that makes it easy to deliver the drugs.
Track 4: Biomarkers and diseases
Next generation sequencing or high-throughput sequencing involves in DNA sequencing and RNA sequencing which is quick and cheap than the previously used method called Sanger sequencing and also there is a revolution in the study of genomics and molecular biology due to the Next-generation Sequencing. Genetic based biomarkers are the biomarkers that are involved in the process of representing genes and genetic products as the biomarkers. Thus genome sequencing using next generation sequencing helps in the discovery of biomarkers.
Track 6: Transcriptional Profiling
Transcriptomics is the study of the RNA transcripts (transcriptome) that are produced by the genomes under certain circumstances using high-throughput techniques like microarray analysis. Transcriptional profiling is a technique used to identify the differences in the gene expression between the diseased tissues and the healthy tissues. DNA sequencing, mRNA profiling, Proteomics, and Systems Biology help in the analysis of the transcriptional profiling. Expressed sequence tags and DNA microarrays are the techniques that are used in transcriptional profiling.
Track 7: Biomarkers and Radiology
Biomarkers are detectable parameters which can be biochemical, genetic, histologic, anatomic, physical, functional, or metabolic. They are detected as an image which helps in the diagnosis of the disease that is involved in it. Imaging biomarkers are used in clinical analysis. It promotes research and also leverage advances in bioinformatics.
Track 8: Biomarkers and Pharmacology
Pharmacology is a branch of biology and medicine which deals with the drug actions which creates a biological or physiological effect in the cell, organ or the organism. Biomarkers are the quantitative measurable indicators of the biological processes, therapeutic responses or the pathogenic responses which helps in the study of pharmacology. Thus Biomarkers help in the prediction of the biological reactions that takes place inside the organism, making the drug development process easy.
Track 9: Exposure Response and Susceptibility
Biomarkers of Exposure are the biomarkers that expose the genetic susceptibility to the drug actions or the chemicals that are accumulated in the body. Advances in the study of biomarkers led to the development of analytical techniques to detect and understand the quantity of the natural and synthetic toxins in the biological matrix. Epigenetics is the study of changes in the organisms that are made due to the modifications in the gene expression rather than the alteration in the genetic code. The biomarkers are used to analyze the pharmacodynamics and the toxicodynamics interactions to the pathological reactions and the biochemical reactions that occur in the body.
Track 10: Drug Discovery and Development
The aim of drug discovery and drug development is to find the effective drug and to provide the right dosage at right frequency to the affected organism. The Biomarkers are an effective tool to identify the mechanism of action of the drug that can correlate pharmacokinetics and pharmacodynamics of the drug. Biomarkers help in finding the safe way of drug administration that the patient is safe and the drug is effective to the patient.
Track 11: Clinical Development & Case Studies
Biomarkers are intended to replace the surrogate endpoints in clinical trials. Surrogate markers are used to conduct clinical trial and gather a good number of endpoints which is impractical when the primary end point is undesired or the event number is very small. The Biomarkers help in the diagnostics and the Biomarkers help in the clinical development processes. Biomarkers case study plays an important role in finding and using new treatments to the patients who are in need and new drugs can be used widely in various clinical practices.
Biomarkers play a crucial role in diagnosis and treatment of diseases like cancer, and to enable screening of asymptomatic populations. Omics technologies like transcriptomics, genomics and proteomics approaches are increasing the discovery of biomarkers. The techniques like micro array data analysis, computational biology, data mining methods, Transcriptional profiling techniques are used in validating the biomarkers. Genome-wide association studies have helped in understanding the genetic basis of complex diseases and advances in high-throughput technologies. In the research of Biomarkers the Bioinformatics tools help in promoting better diagnosable parameters. There are various applications of bioinformatics in the biomarker research which are obtained by data mining methods and the genomic, proteomic approaches.
Track 13: Biomarkers and Nanotechnology
Track 14: Biomarker Identification Technique
Biomarkers are the bimolecular indictors of disease condition of biological organisms. The techniques used to identify the biomarkers include micro array data analysis, RT-PCR validations, molecular imaging and molecular dynamics, biochemical assay and profiling, immunological techniques and chromatographic techniques. Biomarkers are identified and analyzed using response surface analysis and biomarker interaction modelling using systems biology. Biomarkers are identified using the above methods and assay development is done further usage of the biomarkers.
Track 15: Biomarkers for Toxicity Prediction
Biomarkers are used for the prediction of Toxicity because these biomarkers act as an indicator when there is a toxic response that takes place in the system. Many qualified biomarkers are being used to predict and detect the toxic reactions that occur in the body. There are many translational biomarkers used in the study of toxins that plays a crucial role in the toxicity prediction.
Track 16: Personalized Medicine
Personalized Medicine is commonly known for its use of genomic information in addition to the family history, environmental factors and lifestyle to manage the health. Accurate predictions can be made about a person’s susceptibility to develop a disease, the course of disease and to respond to the treatment. Personalized Medicine is a new field of research and evidence based literature is required for integrating into healthcare delivery.
Track 17: Advances of Biomarker testing
Biomarker testing also called as genetic testing or molecular testing is a group of tests that looks for the molecular signs of health so that doctors can plan the best care. Molecules can be taken from the blood, body fluids, or any tissues. The patient is tested for Molecular Biomarkers in the genome and genetic testing is done. Testing practices are intensely deliberated influences diagnostic quality.
Track 18: Current Researches in Biomarkers
Current research on Biomarkers includes new therapeutic strategies to solve the issues taking place inside the body. Biomarker research is done in neurology, oncology, glucose disorders and several critical diseases. There are discoveries like biomarkers of exposure for dietary, environmental and metabolic cancer risk factors.
Track 19: Clinical Applications of Biomarkers
There are various clinical applications of Biomarkers in the treatment of cardiovascular diseases, acute kidney injuries, and cancer treatments. The Biomarkers are used in the development of vaccines and drug which is a major application in the field of drug discovery and development.
The worldwide biomarkers market is relied upon to reach $45.55 Billion by 2020 from $24.10 Billion in 2015, at a CAGR of 13.58% somewhere around 2015 and 2020. Expanding medicinal services use and R&D spending and the expanding utility of biomarkers for diagnostics are relied upon to drive the market. Showcase development will likewise be helped by the minimal effort of clinical trials in creating nations and new activities attempted for biomarker inquire about. Then again, the requirement for high capital venture, low advantage cost proportion, ineffectively suited administrative and repayment frameworks, and the high cost of tests and test gathering and capacity are the main considerations controlling the development of this market.
The applications incorporated into this report are diagnostics advancement, sedate disclosure and improvement, customized drug, ailment chance appraisal and different applications. The ailment sign fragments incorporated into this report are growth, cardiovascular disarranges, neurological clutters, immunological scatters, and different illnesses.
Major players in this market include QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (U.S.), Merck & Co, Inc. (U.S.), Bio-Rad Laboratories (U.S.), Enzo Biochem (U.S.), EKF Diagnostics Holdings plc (U.S.), Meso Scale Diagnostics, LLC (U.S.), Singulex, Inc. (U.S.), BioSims Technologies (France), Cisbio Bioassays (France), and Signosis, Inc. (U.S.).
The global cancer biomarkers market has experienced substantial growth over the last couple of years. This market is expected to grow at a CAGR of 11.6% from 2015 to 2020. Factors such as rising incidence of cancer; technological advancements in omics technologies; favorable government funding for cancer research; increased demand for personalized medicines in cancer therapies; and increased use of biomarkers in drug discovery development and clinical trials are expected to fuel the growth of the cancer biomarkers market during the forecast period. The global cancer biomarkers market is expected to reach USD 15,973.8 Million by 2020, at a CAGR of 11.6% from 2015 to 2020.
The global biomarkers market is expected to reach $45.55 Billion by 2020 from $24.10 Billion in 2015, at a CAGR of 13.58% between 2015 and 2020. Increasing healthcare expenditure & R&D spending and the increasing utility of biomarkers for diagnostics are expected to drive the market. Market growth will also be aided by the low cost of clinical trials in developing countries and new initiatives undertaken for biomarker research. On the other hand, the need for high capital investment, low benefit-cost ratio, poorly suited regulatory & reimbursement systems, and the high cost of tests and sample collection & storage are the major factors restraining the growth of this market.
Importance & Scope:
For organizations with a successful system, advertise opportunity is standing by. Significantly, the capacity to build up a powerful system starts with where opportunity exists and finishes with how to adequately execute to catch benefit from circumstance.
The biomarkers advertise presents the biggest of all open doors in delegate malady sub segments. This study researches a standout amongst the most critical market drivers: the presentation of mix treatments, which are relied upon to keep on contributing generously to market development through the gauge time frame. This report investigates developing markets by sickness fragment. Proceeded with development is normal in rising topographies, driven by the developing working class in rising nations, for example, India, China, Brazil and Russia.
This report looks to address the basically imperative points of examining a changing business sector powerful, developing players and advancements, techniques for getting to developing markets, and particular sickness fragments and geologies with a specific end goal to dispense assets and settle on viable choices.
Scope of Report
Present and anticipated item conjectures amid the figure time frame (2013 to 2018) are talked about. What's more, new items endorsed in 2012 and 2013 by the FDA, and those items anticipated that would be affirmed inside the figure time frame, are anticipated. Figures are evaluated for 2013, aside from where genuine results have been accounted for, because of the planning of the arrival of the report. For all regions, including substantial markets sections, for example, irresistible malady and cardiovascular, particular instruments of activity are talked about in detail. Advertise figures incorporate the packaged estimation of the medication and the biomarker as it is difficult to quantify the composite estimations of each.
The report incorporates an examination of driving and rising rivals in the current overall biomarkers advertise. Profiles of makers of driving items and additionally biotechnology organizations with novel items being developed are broke down to characterize their particular item techniques.
to attend Biomarkers Congress 2017?
Biomarkers Congress 2017 intends to convey a flawless stage to the logical and industry work force to share their insight and mastery. It offers chance to direct showings, appropriate data, meet with present and potential speakers/Delegates all around the globe which are chipping away at the extremely developing field of Biomarkers, and get name acknowledgment at this 3-day occasion. Widely acclaimed speakers, the latest procedures, strategies, and the freshest upgrades in Biomarkers and Clinical Research fields are signs of this meeting.
For Biomarkers mainly the target audiences are Universities, Research institutes, Hospitals, Industries, Medical device manufacturing companies, CROs and Associations.
Glance at market of Biomarkers and Clinical Research:
Add up to market estimation of Biomarkers in 2014 is $5.95 Billion and it is relied upon to reach $30 Billion in 2020 developing at CAGR of 16% from 2014 to 2020. Biomarkers real verticals are typically provided by market of use and market of administrations. Normal Annual Growth Rate of more than 37% is picked up by market for application and Common Annual Growth Rate of more than 39% are picked up from the market of administrations. Along these lines the regular yearly development is 49% by income. These days extent of biomarkers has an imperative part in adequacy of the helpful procedure all around the globe. Building up the institutionalization of medication advancement has a noteworthy part for the improvement of illness pathway. Additionally, Research arrangement of biomarkers disclosure has an application in all the major logical studies.